Get the Stockscreener App
27.14
1.20%
-0.33
Upstream Bio Inc stock is traded at $27.14, with a volume of 305.42K.
It is down -1.20% in the last 24 hours and up +14.42% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$27.47
Open:
$28
24h Volume:
305.42K
Relative Volume:
0.70
Market Cap:
$1.47B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-21.13
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-2.20%
1M Performance:
+14.42%
6M Performance:
+134.78%
1Y Performance:
+32.97%
1-Day Range:
$26.78
$28.25
1-Week Range:
$26.78
$29.55
52-Week Range:
$5.14
$33.00
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
27.14 | 1.48B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Financial Analysis: Precision BioSciences (NASDAQ:DTIL) & Upstream Bio (NASDAQ:UPB) - Defense World
Bain Capital Life Sciences Investors LLC Raises Holdings in Upstream Bio, Inc. $UPB - MarketBeat
Norges Bank Acquires New Position in Upstream Bio, Inc. $UPB - MarketBeat
Can Upstream Bio Stock Hold Up When Markets Turn? - Trefis
Contrasting Upstream Bio (UPB) & The Competition - Defense World
Geode Capital Management LLC Buys 235,958 Shares of Upstream Bio, Inc. $UPB - MarketBeat
Lifesci Capital Predicts Upstream Bio FY2025 Earnings - Defense World
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study (UPB) - Seeking Alpha
UPB: Virectib's robust phase 2 results and unique mechanism set the stage for pivotal trials in 2026 - TradingView
Lifesci Capital Forecasts Upstream Bio FY2025 Earnings - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
Stocks of Upstream Bio Inc (UPB) are poised to climb above their peers - setenews.com
Upstream Bio (NASDAQ:UPB) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat
Upstream Bio (NASDAQ:UPB) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Upstream Bio (UPB) with Outperform Recommendation - Nasdaq
Upstream Bio initiated with an Outperform at LifeSci Capital - TipRanks
Is Upstream Bio Inc. stock attractive for ETFsJuly 2025 Snapshot & Fast Moving Stock Watchlists - Newser
What analysts say about Upstream Bio Inc stockEarnings Miss Alerts & Free High Yield Market Plays - earlytimes.in
Why retail investors favor Upstream Bio Inc. stockJuly 2025 Highlights & Detailed Earnings Play Alerts - BỘ NỘI VỤ
Severe Asthma Clinical Pipeline 2025: A Comprehensive Review of 50+ Emerging Therapies from 40+ Innovators, says DelveInsight - Barchart.com
You might want to take a look at Upstream Bio Inc (UPB) now - Setenews
Upstream Bio (NASDAQ:UPB) Shares Up 8.5%Should You Buy? - MarketBeat
Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge - Yahoo Finance
Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements - TipRanks
Upstream Bio to Participate in Upcoming December Investor Conferences - The Manila Times
Upstream Bio stock reaches 52-week high at 26.99 USD By Investing.com - Investing.com Canada
Upstream Bio stock reaches 52-week high at 26.99 USD - Investing.com India
Commit To Buy Upstream Bio At $20, Earn 80.2% Annualized Using Options - Nasdaq
Why Upstream Bio Inc. stock is popular among millennialsEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - newser.com
How strong is Upstream Bio Inc. stock revenue growthEarnings Miss & Stock Portfolio Risk Management - newser.com
What risks investors should watch in Upstream Bio Inc. stock2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Using data filters to optimize entry into Upstream Bio Inc.Earnings Recap Summary & Daily Stock Momentum Reports - newser.com
Top investors say Upstream Bio Inc (UPB) ticks everything they need - Setenews
Evercore ISI Begins Coverage on Upstream Bio (NASDAQ:UPB) - MarketBeat
Upstream Bio (NASDAQ:UPB) Now Covered by Evercore ISI - Defense World
Upstream Bioprocessing Market on Track for Strong Growth, Estimated to Grow at 12.4% CAGR Through 2029 - openPR.com
Analyzing Upstream Bio Inc. with multi timeframe chartsTrade Entry Report & Risk Adjusted Swing Trade Ideas - newser.com
Upstream Bio, Inc.Common Stock (NQ: UPB - FinancialContent
Evercore ISI Group Initiates Coverage of Upstream Bio (UPB) with Outperform Recommendation - Nasdaq
Upstream Bio initiated with an Outperform at Evercore ISI - MSN
Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets - TipRanks
Why hedge funds are buying Upstream Bio Inc. stockTrade Analysis Summary & Verified Entry Point Detection - newser.com
What earnings revisions data tells us about Upstream Bio Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Ranking Upstream Bio Inc. among high performing stocks via toolsJuly 2025 Rallies & Daily Price Action Insights - newser.com
Can momentum traders help lift Upstream Bio Inc.Earnings Risk Summary & Smart Investment Allocation Insights - newser.com
Is Upstream Bio Inc. stock trading at a premium valuationEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
Can Upstream Bio Inc. stock resist sector downturnsShort Setup & Real-Time Volume Triggers - newser.com
Candlestick signals on Upstream Bio Inc. stock todayPortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
Is Upstream Bio Inc. stock dividend yield sustainable2025 Breakouts & Breakdowns & AI Forecast for Swing Trade Picks - newser.com
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):